Dariohealth reports first quarter 2025 financial and operating results

First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (b2b2c) growth, and a decrease of 11% sequentially. gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024 gross margin (non-gaap) increased to 70.5%, up from 62.4% in the first quarter of 2024 operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional efficiencies anticipated through ongoing ai-driven process optimization gaap operating loss decreased by 47% compared to the first quarter of 2024, improving to $9.4 million non-gaap operating loss decreased by 36% compared to the first quarter of 2024, improving to $5.8 million 14 new clients signed year-to-date, including a national health plan, regional plan, 12 employers, and two pharma companies  strategic platform expansion through glp-1 prescribing (mediorbis), behavioral health (rula), and cardiometabolic support via a national benefit plan administrator glp-1 solution expanded with virtual prescribing and integration into chronic condition programs artificial intelligence (ai) transformation underway, automating workflows, lowering costs, and enhanced operational scalability refinanced debt and raised equity, strengthening balance sheet, extending cash runway and providing operating flexibility to drive strategic plans dario remains on track to achieve operational cash flow breakeven run rate by the end of 2025 given existing account expansion, new contract wins and a pipeline of near-term opportunities  dario will host an investor conference call and webcast at 8:30 a.m.
DRIO Ratings Summary
DRIO Quant Ranking